Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opthea Limited

http://www.opthea.com/

Latest From Opthea Limited

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Financing Growth

Pipeline Watch: Phase III Progress With Semaglutide, Sotagliflozin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Chugai deal positions Circadian as "dominant" player in VEGF-D rights

Roche's Japanese subsidiary, Chugai, has granted the Australian bioventure Circadian exclusive worldwide rights to its intellectual property (IP) estate in the area of vascular endothelial growth factor D (VEGF-D).

Cancer Finland
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Ceres Oncology Pty Ltd
    • Circadian Technologies Limited
    • Opthea Pty Ltd
    • Vegenics Pty Limited
UsernamePublicRestriction

Register